{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0"},{"groupId":"OG001","value":"88.9"},{"groupId":"OG002","value":"83.3"},{"groupId":"OG003","value":"100.0"}]}],"title":"Day 5 (total=4, 9, 6, 8)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0"},{"groupId":"OG001","value":"100.0"},{"groupId":"OG002","value":"80.0"},{"groupId":"OG003","value":"100.0"}]}],"title":"Day 8 (total = 4, 7, 5, 7)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3"},{"groupId":"OG001","value":"37.5"},{"groupId":"OG002","value":"80.0"},{"groupId":"OG003","value":"100.0"}]}],"title":"Day 10 (Total=3, 8, 5, 7)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.0"},{"comment":"no patients with positive reading (greater than two fold increased when compared to baseline) at this time point in the dose group.","groupId":"OG001","value":"NA"},{"groupId":"OG002","value":"50.0"},{"groupId":"OG003","value":"50.0"}]}],"title":"Day 12 (Total=4, 6, 4, 8)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.0"},{"groupId":"OG001","value":"50.0"},{"groupId":"OG002","value":"100.0"},{"groupId":"OG003","value":"60.0"}]}],"title":"Day 15 (Total=4, 6, 2, 5)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"75.0"},{"groupId":"OG002","value":"50.0"},{"groupId":"OG003","value":"0.0"}]}],"title":"End of Study (Total=1, 4, 2, 0)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0"},{"comment":"No patients were analyzed for this arm.","groupId":"OG001","value":"NA"},{"comment":"No patients were analyzed for this arm.","groupId":"OG002","value":"NA"},{"comment":"No patients were analyzed for this arm.","groupId":"OG003","value":"NA"}]}],"title":"Unscheduled (Total=2, 0, 0, 0)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"9"}],"units":"Participants"}],"groups":[{"description":"Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF)","id":"OG000","title":"Arm 2, Group X (30 mg)"},{"description":"Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF)","id":"OG001","title":"Arm 2, Group X (45 mg)"},{"description":"Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF)","id":"OG002","title":"Arm 2, Group X (60 mg)"},{"description":"Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF)","id":"OG003","title":"Arm 2, Group X (80 mg)"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set","reportingStatus":"POSTED","timeFrame":"Days 5, 8, 10, 12, 15, End of study, Unscheduled (up to 3.5 years)","title":"Percentages of Participants With Histone Acetylation Induction in Peripheral Blood in Arm 2 (MWF Every Other Week), Group X","type":"SECONDARY","unitOfMeasure":"Percentages of participants"}